OptimizeRx Corp — Director's Dealing 2023

Apr 3, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OptimizeRx Corp (OPRX)
CIK: 0001448431
Period of Report: 2023-03-31

Reporting Person: Vos Ellen O'Connor (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-31	Common Stock	M	657	—	Acquired	34790	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-03-31	Restricted Stock Units	$	M	657	Disposed		Common Stock (657.0)	Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: On March 30, 2022 the reporting person was granted 657 restricted stock units which vested in full on March 30, 2023.